Raúl Martín


Raúl coordinates the identification and evaluation of investment opportunities from the scientific and business perspectives. He also directs the preparation of the scientific and business reporting to the Investment Committee and collaborates in the monitoring of Ysios’s portfolio companies.

Raúl serves on the board of MedLumics, Anaconda Biomed and Corwave. Formerly he was board member at Prexton Therapeutics, acquired by Lundbeck, and STAT-Dx, acquired by Qiagen.

Prior to joining Ysios in 2008, Raúl worked at Almirall where he was responsible for managing and developing the company’s business through licensees and distributors in America and Africa. Before that, he worked in Almirall’s corporate business development department, focusing on in- and out-licensing. At Almirall he interacted with numerous pharmaceutical and biotech companies on a global basis and coordinated and led evaluation and approval several licensing projects in different therapeutic areas, from the technical, commercial, contractual, financial and business perspectives.

Raúl began his career in research. He worked on central nervous system pharmacology in the department of pharmacology of the University of the Basque Country (UPV/EHU), and on neurochemistry in the department of neurochemistry of the Institute for Biomedical Research of Barcelona (IIBB)- Spanish National Research Council (CSIC).

Raúl holds a bachelor’s of science in biological sciences from UPV/EHU and a PhD in neurosciences from UPV/EHU and CSIC.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

Aviso de cookies